<?xml version="1.0" encoding="UTF-8"?>
<ref id="B84">
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Haga</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Nagata</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Okamura</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>N.</given-names>
   </name>
   <name>
    <surname>Sata</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Yamamoto</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group> (
  <year>2010</year>). 
  <article-title>TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds.</article-title>
  <source>
   <italic>Antiviral Res.</italic>
  </source>
  <volume>85</volume>
  <fpage>551</fpage>â€“
  <lpage>555</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.001</pub-id>
  <?supplied-pmid 19995578?>
  <pub-id pub-id-type="pmid">19995578</pub-id>
 </mixed-citation>
</ref>
